Squamous Cell Carcinoma of Head and Neck Clinical Trials in Boston, Massachusetts
8 recruitingBoston, Massachusetts
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC500 enrolled186 locationsNCT07276399
Recruiting
Phase 1Phase 2
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC287 enrolled56 locationsNCT06385080
Recruiting
Phase 1
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of Head and Neck
Johnson & Johnson Enterprise Innovation Inc.30 enrolled16 locationsNCT07219212
Recruiting
Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled159 locationsNCT04389632
Recruiting
Early Phase 1
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
Head and Neck CancerSquamous Cell Carcinoma of Head and NeckSalivary Gland Cancer+1 more
Brigham and Women's Hospital30 enrolled2 locationsNCT05553782
Recruiting
Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Colorectal, CancerSquamous Cell Carcinoma of Head and NeckHead and Neck Squamous Cell Carcinoma+8 more
Bicara Therapeutics292 enrolled20 locationsNCT04429542
Recruiting
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of Head and Neck
Massachusetts Eye and Ear Infirmary75 enrolled1 locationNCT06744296
Recruiting
Phase 2
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
MelanomaSquamous Cell Carcinoma of Head and Neck
IO Biotech60 enrolled15 locationsNCT05280314